JP2004529118A - インテグリンリガンドを有する酵素活性化細胞分裂停止接合体 - Google Patents

インテグリンリガンドを有する酵素活性化細胞分裂停止接合体 Download PDF

Info

Publication number
JP2004529118A
JP2004529118A JP2002571109A JP2002571109A JP2004529118A JP 2004529118 A JP2004529118 A JP 2004529118A JP 2002571109 A JP2002571109 A JP 2002571109A JP 2002571109 A JP2002571109 A JP 2002571109A JP 2004529118 A JP2004529118 A JP 2004529118A
Authority
JP
Japan
Prior art keywords
substituted
group
unsubstituted
conjugate
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002571109A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004529118A5 (fr
Inventor
ハンス−ゲオルク・ラーヒェン
イェルク・バウムガルテン
アンドレアス・ショープ
マルクス・アルベルス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer AG filed Critical Bayer AG
Publication of JP2004529118A publication Critical patent/JP2004529118A/ja
Publication of JP2004529118A5 publication Critical patent/JP2004529118A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2002571109A 2001-03-08 2002-03-07 インテグリンリガンドを有する酵素活性化細胞分裂停止接合体 Pending JP2004529118A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01105350A EP1238678A1 (fr) 2001-03-08 2001-03-08 Conjugués d'agents cytostatiques et de ligands d'intégrine activés par des enzymes
PCT/EP2002/002501 WO2002072151A1 (fr) 2001-03-08 2002-03-07 Conjugues cytostatiques actives par voie enzymatique comprenant des lignads de l'integrine

Publications (2)

Publication Number Publication Date
JP2004529118A true JP2004529118A (ja) 2004-09-24
JP2004529118A5 JP2004529118A5 (fr) 2005-12-22

Family

ID=8176682

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002571109A Pending JP2004529118A (ja) 2001-03-08 2002-03-07 インテグリンリガンドを有する酵素活性化細胞分裂停止接合体

Country Status (5)

Country Link
US (2) US7304037B2 (fr)
EP (2) EP1238678A1 (fr)
JP (1) JP2004529118A (fr)
CA (1) CA2439897A1 (fr)
WO (1) WO2002072151A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022506299A (ja) * 2018-11-05 2022-01-17 バイエル ファーマ アクチェンゲゼルシャフト インテグリンリガンドを有する新規な細胞増殖抑制コンジュゲート

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102453036B (zh) * 2010-10-27 2015-12-02 李红玉 一种喜树碱类化合物及其制备方法和在农药中的用途
US9737556B2 (en) 2014-06-13 2017-08-22 Trustees Of Tufts College FAP-activated therapeutic agents, and uses related thereto
PL3154594T3 (pl) 2014-06-13 2023-10-09 Bach Biosciences, Llc Środki terapeutyczne aktywowane FAP i związane z nimi zastosowania
CN109575051B (zh) * 2019-01-23 2021-07-27 遵义医科大学 一种天然药物成分修饰衍生物及其抗肿瘤应用
CN115996756A (zh) 2020-05-08 2023-04-21 博尔特生物治疗药物有限公司 弹性蛋白酶底物肽连接子免疫缀合物及其用途
WO2023057812A1 (fr) 2021-10-04 2023-04-13 Vincerx Pharma Gmbh Composés, compositions pharmaceutiques et méthodes pour le traitement, la prévention ou la gestion d'un trouble hyperprolifératif
WO2023057814A1 (fr) 2021-10-04 2023-04-13 Vincerx Pharma Gmbh Composés, compositions pharmaceutiques et méthodes de traitement, de prévention ou de gestion de troubles hyperprolifératifs
WO2023057813A1 (fr) 2021-10-04 2023-04-13 Vincerx Pharma Gmbh Composés, compositions pharmaceutiques et méthodes pour le traitement, la prévention ou la gestion de troubles hyperprolifératifs
WO2024105197A1 (fr) 2022-11-17 2024-05-23 Vincerx Pharma Gmbh Conjugués médicament-petites molécules clivables dans un micro-environnement tumoral

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3611194A1 (de) * 1986-04-04 1987-10-08 Bayer Ag Cancerostatisches mittel
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
US4975278A (en) * 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US4980343A (en) * 1988-10-27 1990-12-25 Bayer Aktiengesellschaft Aminooxodihydroisoindoloquinazoline carcinostatic agents
CA2076982A1 (fr) 1990-12-27 1992-06-28 Akira Okura Derives d'acide pyridonecarboxylique
US5561116A (en) * 1991-04-11 1996-10-01 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Solid product containing propolis components, and preparation and uses thereof
FR2676058B1 (fr) 1991-04-30 1994-02-25 Hoechst Lab Prodrogues glycosylees, leur procede de preparation et leur utilisation dans le traitement des cancers.
DE4120646A1 (de) * 1991-06-22 1992-12-24 Bayer Ag 7-isoindolinyl-chinolon- und naphthyridoncarbonsaeure-derivate
DE4229903A1 (de) 1992-09-08 1994-03-10 Bayer Ag Neue Acetale von Ketophosphamid und Alkylglycosiden
DE4236237A1 (de) 1992-10-27 1994-04-28 Behringwerke Ag Prodrugs, ihre Herstellung und Verwendung als Arzneimittel
US5646159A (en) 1994-07-20 1997-07-08 Research Triangle Institute Water-soluble esters of camptothecin compounds
DE19512484A1 (de) 1995-04-04 1996-10-17 Bayer Ag Kohlenhydratmodifizierte Cytostatika
WO1998010795A2 (fr) * 1996-09-10 1998-03-19 The Burnham Institute Molecules se logeant dans une tumeur, conjugues tires de ces molecules et leurs procedes d'utilisation
ID23424A (id) 1997-05-14 2000-04-20 Bayer Ag Glikokonjugat dari 20(s)-kamptotesin
CA2325342A1 (fr) * 1998-04-08 1999-10-14 G.D. Searle & Co. Ligands doubles du recepteur avb3 et du recepteur associe aux metastases
US6291503B1 (en) * 1999-01-15 2001-09-18 Bayer Aktiengesellschaft β-phenylalanine derivatives as integrin antagonists
EP1181055A2 (fr) * 1999-05-14 2002-02-27 Boehringer Ingelheim Pharmaceuticals Inc. Composes de promedicaments anti-tumoraux actives par des enzymes
RU2002109215A (ru) * 1999-09-08 2003-12-10 Байер Акциенгезельшафт (De) Индуцированное интегрином влияние на место действия лекарственного средства

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022506299A (ja) * 2018-11-05 2022-01-17 バイエル ファーマ アクチェンゲゼルシャフト インテグリンリガンドを有する新規な細胞増殖抑制コンジュゲート
JP7509768B2 (ja) 2018-11-05 2024-07-02 バイエル ファーマ アクチェンゲゼルシャフト インテグリンリガンドを有する新規な細胞増殖抑制コンジュゲート

Also Published As

Publication number Publication date
US7304037B2 (en) 2007-12-04
EP1372732A1 (fr) 2004-01-02
CA2439897A1 (fr) 2002-09-19
US20080108576A1 (en) 2008-05-08
US20020193311A1 (en) 2002-12-19
EP1238678A1 (fr) 2002-09-11
WO2002072151A1 (fr) 2002-09-19

Similar Documents

Publication Publication Date Title
US20080108576A1 (en) Novel cytostatic conjugates with integrin ligands
DK2678037T3 (en) Branched linker for protein pharmaceutical conjugates
JP6539729B2 (ja) ペプチド−薬物複合体
EP0950665A1 (fr) Proteines modifiees physiologiquement actives et compositions medicamenteuses les contenant
EP4162955A1 (fr) Promédicaments du cnp ayant le transporteur fixé sur la partie cyclique du peptide
TR201802124T4 (tr) Adrenomedullin'in polietilen glikol temelli ön ilacı ve bunun kullanımı.
TW201004647A (en) Novel dual targeting antitumoural conjugates
US20060189544A1 (en) Integrin-Mediated drug targeting
CA2267328A1 (fr) Glycoconjugues a base de derives modifies de camptothecine (20-o-liaison)
AU744425B2 (en) 20(s) camptothecin glycoconjugates
CA3193485A1 (fr) Conjugues peptidiques de sn38 utiles dans le traitement du cancer
US20020173468A1 (en) Modified cytostatic agents
US20020183256A1 (en) Cytostatic-integrin conjugates having specifically cleavable linking units
US20020173452A1 (en) Cytostatic-glycoconjugates having specifically cleavable linking units
US7220824B1 (en) Integrin-mediated drug targeting
CZ401799A3 (cs) Glykokonjugáty 20(S)-camptothecinu, způsob jejich výroby, jejich použití a léčiva tyto látky obsahující

Legal Events

Date Code Title Description
A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050202

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050202

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20071218

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080225

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080303

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080408

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080415

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080501

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080512

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080610

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090217